Document is current

Article History

Accepted: 28 May 2025

First Online: 16 July 2025

Declarations

:

: This study was sponsored by Takeda Development Center Americas, Inc. Takeda Development Center Americas, Inc., provided funding to Envision Catalyst, an Envision Medical Communications agency, a part of Envision Pharma Group for support in writing and editing this article.

: Maureen Watt is an employee of Takeda Development Center Americas, Inc., and holds stock/options in Takeda Pharmaceutical Company Limited. Rose Chang, Louise Huafeng Yu, Louise Clear, and Maral DerSarkissian are employees of Analysis Group, which was contracted by Takeda Development Center Americas, Inc. to perform this study.

: The study was conducted in accordance with the Good Publication Practice guidelines of the International Society for Pharmacoepidemiology. Central institutional review board exemption determination was provided by the Pearl Institutional Review Board (date: 01/03/2023, protocol number 22-ANGR-127); patient data were de-identified, and patient informed consent was not required.

: Physicians provided their consent to participate in the physician panel for this study.

: Not applicable.

: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

: Not applicable.

: MW, RC, LHY, LC, and MD contributed to the design of the study. MW, RC, LHY, LC, and MD were involved in the analysis and interpretation of the data. MW, RC, LHY, LC, and MD were involved in drafting the manuscript and revising it critically. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.